查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球注射器市场：预测（2023-2028）
市场调查报告书
商品编码
1410183

全球注射器市场：预测（2023-2028）

Global Syringe Market - Forecasts from 2023 to 2028
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 112 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计2028年全球注射器市场规模将达99.08亿美元，2023年至2028年复合年增长率为3.50%。

老年人口的增加是预测期内推动注射器产业成长的关键因素之一。老年人口的增加对注射器需求的增加产生了直接的正面影响，因为许多人随着年龄的增长而生病。根据世界银行资料，到2050年，65岁以上人口将达12.5亿，比2020年增加约7570亿。

慢性病增加

全球慢性病盛行率上升也是预期导致预测期内注射器需求增加的主要因素。例如，预计2021年全球糖尿病患者人数将达5.37亿，2030年将达6.43亿，2045年将达7.83亿。此外，预计到 2021 年将有 5.41 亿人出现糖耐量受损。此外，世界各地实施的免疫计划数量不断增加，人们对接种疫苗来应对各种疾病的认识不断提高，也有助于注射器市场在预测期内的增长。

非传染性疾病死亡率

由于现代生活方式缺乏其他活动，许多人患有各种慢性疾病，如类风湿性关节炎、糖尿病等。根据世界卫生组织（WHO）统计，每年发生的1,790万例非传染性疾病中，大部分是由心血管疾病引起的，其中包括恶性（930万例）、慢性呼吸道疾病（410万例）和糖尿病（糖尿病肾病变） ). 其次是 200 万人（包括疾病死亡）。预计这将对注射器市场的成长产生积极影响，并有望补充注射器使用量的增加。

美国的慢性病

根据疾病管制与预防中心的数据，美国近十分之六的成年人患有慢性病，十分之四的人患有两种或两种以上慢性病。此外，根据国际糖尿病联盟的数据，糖尿病患者人数预计将从 2021 年的 5.37 亿增加到 2030 年的 6.34 亿。因此，越来越多的人需要定期注射胰岛素。全球糖尿病患者人数的上升趋势以及领先公司不断推出的市场产品预计将在未来几年持续下去，并预计在评估期间推动注射器的需求。

美国注射器市场预计将稳定成长。

美国注射器的成长是由于该国糖尿病和癌症等慢性疾病的盛行率不断上升。在美国，糖尿病患者正以显着的速度增加。根据美国疾病管制与预防中心的数据，2022 年，有 3,730 万人（即美国美国的 11.3%）患有糖尿病，其中 2,870 万人被诊断出患有糖尿病，850 万人患有未确诊的糖尿病。在美国，18 岁以上的人中有 9,600 万人患有前期糖尿病。因此，此类疾病在美国的盛行率正在增加，这正在推动注射器市场的成长。

美国移植数量

根据器官共享联合网路的数据，美国共有 42,887 例移植手术，较 2021 年增加了 3.7%。 2022年肾臟移植数量为25,498例，与前一年同期比较增加3.4%，其次为肝臟移植9,528例，心臟移植4,111例，肺移植2,692例。随着美国疾病数量和治疗方法的不断增加，注射器市场有望进一步扩大。

市场主要发展

2022 年10 月，泰尔茂(Terumo) 的一个部门、主要容器、注射剂和输液治疗设备製造商泰尔茂製药解决方案(TPS) 宣布推出一款容量更大的即用型聚合物注射器，可应对具有挑战性的生物製药应用。 PLAJEX 2.25 mL 锥形针专为生物技术领域开发，适用于高黏度生物技术药物等困难的药物应用。 2022年1月，总部位于美国西哥伦比亚的Nephron Pharmaceuticals Corporation推出了环烯烃共聚物（COC）注射器。这款 COC 注射器具有玻璃般的外观，但不易破碎且重量轻。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表

第二章调查方法

  • 调查资料
  • 先决条件

第三章执行摘要

  • 研究亮点

第四章市场动态

  • 市场驱动因素
  • 市场抑制因素
  • 波特五力分析
  • 产业价值链分析

第五章全球注射器市场：按类型

  • 介绍
  • 胰岛素注射器
  • 传统注射器
    • 偏心尖头注射器
    • 导管尖端注射器
    • 鲁尔锁注射器

第六章全球注射器市场：依材料分类

  • 介绍
  • 玻璃
  • 塑胶
  • 不銹钢

第七章全球注射器市场：依注射器尺寸分类

  • 介绍
  • 小容量注射器
  • 大容量注射器

第八章全球注射器市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 台湾
    • 泰国
    • 印尼
    • 其他的

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作

第十章 公司简介

  • Becton, Dickinson and Company
  • B. Braun Melsungen
  • Terumo
  • Teleflex
  • Nipro
  • Smith's Medical
  • Cardinal Health
  • HMD Healthcare
  • Hamilton Company
  • Advancecare Pharma USA
简介目录
Product Code: KSI061611594

The global syringe market is estimated to reach a value of US$9.908 billion in 2028 at a CAGR of 3.50% from 2023 - 2028.

The rise in the geriatric population is one of the major factors anticipated to propel the growth of the global syringe industry during the forecast period. As many people acquire diseases as they age, the increasing elderly population has a direct positive impact on the rising demand for syringes. According to data from the World Bank, there will be 1.25 billion individuals aged 65 and older by 2050, an increase of about 757 million from 2020.

Rising prevalence of chronic diseases

The rising prevalence of chronic diseases worldwide is another major factor that is expected to lead to the rising demand for syringes during the forecasted period. For instance, the number of persons with diabetes worldwide was predicted to reach 537 million in 2021, 643 million in 2030, and 783 million in 2045. Additionally, it is anticipated that 541 million individuals will have reduced glucose tolerance by 2021. Moreover, an increasing number of immunization programs being conducted around the world, coupled with increased awareness among people for the need for immunization to tackle various diseases, is anticipated to bolster the growth of the global syringe market during the forecast period.

Death rate by non-communicable diseases

Owing to the lack of physical activities in the modern lifestyle, a number of people suffer from various kinds of chronic diseases like cardiovascular diseases, rheumatoid arthritis, and diabetes, among many others. According to the World Health Organization (WHO), the majority of NCDs, or 17.9 million fatalities each year, are caused by cardiovascular illnesses, followed by malignancies (9.3 million), chronic respiratory conditions (4.1 million), and diabetes (2.0 million, including deaths from renal disease brought on by diabetes). This is expected to have a positive impact on the global syringe market growth and is anticipated to supplement the rise in the use of syringes.

Chronic diseases in Americans

The Centers for Disease Control and Prevention states that nearly six in ten adults in the United States have a chronic disease while four in ten adults have two or more chronic diseases. Furthermore, according to the International Diabetes Federation, the number of people with diabetes is projected to grow from 537 million in 2021 to 634 million in 2030. This is leading to an increased number of people who need regular insulin injections. The increasing trend for diabetics around the world and the increased launch of market products by the major players is projected to continue in the coming years and is anticipated to boost the demand for syringes during the assessment period.

It is projected that the syringe market in the United States will grow steadily.

The growth of syringes in the United States can be attributed to the rising prevalence of chronic diseases like diabetes and cancer in the country. Diabetes is increasing at a significant rate in the United States. According to the Centers for Disease Control and Prevention in 2022, 37.3 million people or 11.3% of the US population were suffering from diabetes, out of which 28.7 million people had been diagnosed with diabetes and 8.5 million people suffered from undiagnosed diabetes. 96 million people aged 18 years or older have become prediabetes in the United States. Hence, the prevalence of such diseases is increasing in the States which in turn is propelling the syringe market growth.

Number of transplants in the United States

According to the United Network for Organ Sharing, the total number of transplants in the United States were 42,887 a 3.7% increase over 2021, and the highest transplants happened for kidney. The kidney transplant statistics for 2022 were 25,498 in the States which is an increase of 3.4% over the previous year, followed by liver, heart, and lung transplants with 9,528, 4,111, and 2,692 transplants respectively. Therefore, with an increase in diseases and an increase in ways to treat them growing in the country, this will help in further expanding the global syringe market in the United States.

Market Key Developments

  • In October 2022, a ready-to-fill polymer syringe with a greater volume for difficult biotech medications was introduced by Terumo Pharmaceutical Solutions (TPS), a part of Terumo Corporation and maker of primary container, injection, and infusion treatment devices. Specifically created for the biotech sector, the PLAJEX 2.25 mL with Tapered Needle is appropriate for difficult drug applications, such as high-viscosity biotech drugs.
  • In January 2022, Nephron Pharmaceuticals Corporation, a company based in West Columbia, United States, launched the Cyclic Olefin Copolymer syringe (COC). These COC syringes have a glass-like appearance, but they are break-resistant and lightweight.

Segmentation:

By Type

  • Insulin Syringe
  • Conventional Syringe
  • Eccentric Tip Syringe
  • Catheter Tip Syringe
  • Luer Lock Syringe

By Material

  • Glass
  • Plastic
  • Stainless Steel

By Syringe Size

  • Smaller Volume Syringe
  • Larger Volume Syringe

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. GLOBAL SYRINGE MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Insulin Syringe
  • 5.3. Conventional Syringe
    • 5.3.1. Eccentric Tip Syringe
    • 5.3.2. Catheter Tip Syringe
    • 5.3.3. Luer Lock Syringe

6. GLOBAL SYRINGE MARKET BY MATERIAL

  • 6.1. Introduction
  • 6.2. Glass
  • 6.3. Plastic
  • 6.4. Stainless Steel

7. GLOBAL SYRINGE MARKET BY SYRINGE SIZE

  • 7.1. Introduction
  • 7.2. Smaller Volume Syringe
  • 7.3. Larger Volume Syringe

8. GLOBAL SYRINGE MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Others
  • 8.6. Asia Pacifi
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Taiwan
    • 8.6.6. Thailand
    • 8.6.7. Indonesia
    • 8.6.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations

10. COMPANY PROFILES

  • 10.1. Becton, Dickinson and Company
  • 10.2. B. Braun Melsungen
  • 10.3. Terumo
  • 10.4. Teleflex
  • 10.5. Nipro
  • 10.6. Smith's Medical
  • 10.7. Cardinal Health
  • 10.8. HMD Healthcare
  • 10.9. Hamilton Company
  • 10.10. Advancecare Pharma USA